Drugmaker GlaxoSmithKline has applied for both U.S. Food and Drug Administration and European approval for its new allergy medicine, Allermist. Allermist (fluticasone furoate) has shown success in clinical trials in treating the symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in both children and adults.
Read moreA cure for asthma is not likely. That's the bad news. The good news is that asthma deaths have decreased and advances in... Read more »
While the economy sputters, the long acting bronchodilator/ corticosteroid combination inhaler market is booming. While big ... Read more »
Developing new medications and getting them from the lab to your neighborhood pharmacy (or mailbox) as safe and effective - is a long,... Read more »
Chances are if you have asthma you have some degree of chronic (it's always there) inflammation in your air passages. Studies have... Read more »
A new study by drugmaker GlaxoSmithKline has found that Advair (fluticasone propionate, salmeterol) and Flovent (fluticasone propionate) appear to be... Read more »
This is a study to compare the effects of Flovent (fluticasone propionate), Advair (fluticasone propionate/salmeterol), and Singulair (montelukast)... Read more »
This is a study to measure the asthma control of Flovent (fluticasone propionate) and salmeterol in children and teens whose asthma is worsened by... Read more »
Patients whose asthma is not controlled by taking fluticasone propionate (Flovent) alone may benefit from taking antileukotriene drugs with the... Read more »
GlaxoSmithKline is conducting a clinical trial to see if fluticasone propionate plus salmeterol (Advair) is better than fluticase propionate alone... Read more »